Fosters Innovation for the Medicare Drug Price Negotiation Program – A new proposal from the CMS would establish a permanent framework for the Medicare Drug Price Negotiation Program, creating a more transparent and sustainable process for lowering drug costs for millions of Medicare beneficiaries.
Read More
By Tom Dorsett – Drug costs are skyrocketing, but why? First we must understand the cause of high drug costs in order to properly address the problem. For more than twenty-five years, I’ve seen drug costs grow and dominate pharmacy budgets across the United States.
By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?